DNLI
Denali Therapeutics Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-12/100
Last price
19.28
▼ 0.63 (3.16%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
19.75
Prev close
19.91
Day high
19.97
Day low
19.03
Volume
3.67M
Market cap
$3.08B
P/E (TTM)
—
52W range
13.75 – 27.30
Day trading desk
Gap from prior close
-0.80%
Prior close 19.91
VWAP
19.41
-0.66% from price
Relative volume
4.22×
Unusually busy
Session range
5.82%
18.90 – 20.00
Position in range
35%
Mid range
ATR (14D)
0.86
4.45% of price
Prior day high
20.09
PDH
Prior day low
19.53
PDL
Bid / ask spread
—
Quote not published
Session volume
6.64M
Avg 1.58M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-7.35%
-9.3%
1M
-13.46%
-14.6%
3M
-27.76%
-32.3%
6M
-0.67%
-18.9%
YTD
+16.78%
+2.5%
1Y
+25.03%
+8.6%
3Y
-6.54%
-88.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on DNLI open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+71.17K
Net buying
Buy transactions
9
89.89K shares
Sell transactions
4
18.72K shares
Net transactions
+13
Buys less sells
Sell : buy shares
0.2 : 1
Mixed
Insider-held shares
7.36M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 4, 26 | CHIN PETER SCOTT Officer |
SELL | 1.65K | $36.87K | Direct |
| Sep 2, 26 | THORNBERRY NANCY A. Director |
SELL | 11.44K | $261.93K | Direct |
| Sep 1, 26 | SCHUTH ALEXANDER O Chief Operating Officer |
SELL | 2.77K | $64.88K | Direct |
| Aug 12, 26 | WATTS RYAN J Chief Executive Officer |
STOCK | 32.22K | $0 | Indirect |
| Aug 11, 26 | SCHUTH ALEXANDER O Chief Operating Officer |
SELL | 2.86K | $71.63K | Direct |
| Jun 3, 26 | COOK JENNIFER E Director |
STOCK | 6.41K | $0 | Direct |
| Jun 3, 26 | BAKER BROS ADVISORS, L.P. Beneficial Owner of more than 10% of a Class of Security |
STOCK | 12.82K | $0 | Indirect |
| Jun 3, 26 | THORNBERRY NANCY A. Director |
STOCK | 6.41K | $0 | Direct |
| Jun 3, 26 | VAN HAUWERMEIREN TIMOTHY Director |
STOCK | 6.41K | $0 | Direct |
| Jun 3, 26 | KROGNES STEVE E Director |
STOCK | 6.41K | $0 | Direct |
| Jun 3, 26 | FLATLEY JAY T Director |
STOCK | 6.41K | $0 | Direct |
| Jun 3, 26 | KLEIN PETER S Director |
STOCK | 6.41K | $0 | Direct |
| Jun 3, 26 | SCHENKEIN DAVID P Director |
STOCK | 6.41K | $0 | Direct |
| Jan 6, 26 | WATTS RYAN J Chief Executive Officer |
SELL | 35.20K | $580.77K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAKER BROS ADVISORS, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Stock Award(Grant) |
CHIN PETER SCOTT |
Officer | 204.54K | Sale |
FLATLEY JAY T |
Director | 358.94K | Stock Award(Grant) |
HO CAROLE |
Officer | 424.80K | Sale |
KROGNES STEVE E |
Director | 820.00K | Stock Award(Grant) |
SATO VICKI LEE |
Director | 107.98K | Sale |
SCHENKEIN DAVID P |
Director | 79.13K | Stock Award(Grant) |
SCHUTH ALEXANDER O |
Chief Operating Officer | 802.74K | Sale |
TESSIER LAVIGNE MARC T |
Director | 2.12M | Stock Award(Grant) |
WATTS RYAN J |
Chief Executive Officer | — | Stock Gift |
Fundamentals
Market cap$3.08B
Enterprise value$2.41B
Revenue (TTM)$3.60M
Gross profit$-397.21M
EBITDA$-526.06M
Net income$-511.45M
EPS (TTM)$-2.75
Free cash flow$-268.53M
Total cash$710.47M
Total debt$37.69M
Book value / share$5.23
Shares outstanding159.85M
Float155.10M
Short % of float11.31%
Dividend yield0.00%
Beta (5Y)1.02
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.97
PEG ratio—
Price / sales—
Price / book3.69
EV / revenue668.44
EV / EBITDA-4.58
Gross margin0.00%
Operating margin-3601.30%
Profit margin0.00%
Return on equity-54.93%
Return on assets-29.15%
Debt / equity4.51
Current ratio8.37
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $330.53M | $108.46M | — |
| Operating revenue | $0 | $0 | $330.53M | $105.06M | — |
| Research & development | $418.78M | $396.44M | $423.88M | $358.73M | +5.6% |
| Selling, general & admin | $136.56M | $105.44M | $103.35M | $90.47M | +29.5% |
| Total operating expense | $555.34M | $501.88M | $527.23M | $449.21M | +10.7% |
| Operating income | -$555.34M | -$501.88M | -$196.70M | -$340.74M | -10.7% |
| Net interest income | $42.90M | $64.64M | $51.51M | $14.77M | -33.6% |
| Pre-tax income | -$512.44M | -$422.70M | -$145.19M | -$325.97M | -21.2% |
| Tax provision | $102.00K | $68.00K | $30.00K | $21.00K | +50.0% |
| Net income | -$512.54M | -$422.77M | -$145.22M | -$325.99M | -21.2% |
| Net income to common | -$512.54M | -$422.77M | -$145.22M | -$325.99M | -21.2% |
| Basic EPS | -2.97 | -2.57 | -1.06 | -2.60 | -15.6% |
| Diluted EPS | -2.97 | -2.57 | -1.06 | -2.60 | -15.6% |
| EBIT | -$555.34M | -$501.88M | -$196.70M | -$340.74M | -10.7% |
| EBITDA | -$540.53M | -$492.89M | -$179.97M | -$330.36M | -9.7% |
| Basic shares | 172.65M | 164.47M | 137.37M | 125.53M | +5.0% |
| Diluted shares | 172.65M | 164.47M | 137.37M | 125.53M | +5.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $205.33M | $174.96M | $127.11M | $218.04M | +17.4% |
| Cash & short-term investments | $867.88M | $832.33M | $1.03B | $1.34B | +4.3% |
| Accounts receivable | $2.18M | $2.17M | $3.42M | $9.28M | +0.3% |
| Total current assets | $900.66M | $864.44M | $1.06B | $1.37B | +4.2% |
| Property, plant & equipment | $119.94M | $125.63M | $71.64M | $74.52M | -4.5% |
| Total assets | $1.14B | $1.37B | $1.15B | $1.46B | -16.7% |
| Total current liabilities | $98.35M | $102.21M | $77.98M | $363.92M | -3.8% |
| Total debt | $36.76M | $48.71M | $52.24M | $60.35M | -24.5% |
| Total liabilities | $131.09M | $144.50M | $122.96M | $417.81M | -9.3% |
| Retained earnings | -$2.05B | -$1.54B | -$1.12B | -$970.99M | -33.3% |
| Shareholder equity | $1.01B | $1.23B | $1.03B | $1.04B | -17.6% |
| Working capital | $802.31M | $762.23M | $986.15M | $1.01B | +5.3% |
| Net tangible assets | $1.01B | $1.23B | $1.03B | $1.04B | -17.6% |
| Shares issued | 156.18M | 144.22M | 138.39M | 135.97M | +8.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$512.54M | -$422.77M | -$145.22M | -$325.99M | -21.2% |
| Depreciation & amortisation | $14.81M | $8.99M | $16.73M | $10.38M | +64.7% |
| Stock-based compensation | $99.63M | $102.88M | $108.10M | $99.85M | -3.2% |
| Change in working capital | $149.00K | $16.94M | -$289.93M | -$24.03M | -99.1% |
| Operating cash flow | -$412.60M | -$347.69M | -$357.99M | -$244.72M | -18.7% |
| Capital expenditure | -$9.50M | -$15.91M | -$12.94M | -$17.83M | +40.3% |
| Investing cash flow | $255.28M | -$88.76M | $249.31M | -$141.39M | +387.6% |
| Financing cash flow | $189.22M | $484.30M | $17.82M | $310.67M | -60.9% |
| Free cash flow | -$422.10M | -$363.61M | -$370.93M | -$262.55M | -16.1% |
| End cash position | $208.43M | $176.53M | $128.68M | $219.54M | +18.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $3.60M | $0 | $0 | $0 | $0 | — |
| Operating revenue | $3.60M | $0 | $0 | $0 | $0 | — |
| Cost of revenue | $93.00K | — | — | — | $0 | — |
| Gross profit | $3.51M | — | — | — | $0 | — |
| Research & development | $97.02M | $103.85M | $97.91M | $101.95M | $102.70M | -6.6% |
| Selling, general & admin | $36.28M | $33.51M | $39.46M | $35.48M | $32.27M | +8.3% |
| Total operating expense | $134.05M | $137.36M | $137.37M | $137.43M | $134.96M | -2.4% |
| Operating income | -$130.54M | -$137.36M | -$137.37M | -$137.43M | -$134.96M | +5.0% |
| Net interest income | $2.99M | $8.91M | $8.92M | $10.53M | $10.84M | -66.5% |
| Pre-tax income | -$127.55M | -$128.45M | -$128.45M | -$126.90M | -$124.12M | +0.7% |
| Net income | -$127.55M | -$128.45M | -$128.55M | -$126.90M | -$124.12M | +0.7% |
| Net income to common | -$127.55M | -$128.45M | -$128.55M | -$126.90M | -$124.12M | +0.7% |
| Basic EPS | -0.68 | -0.69 | -0.73 | -0.74 | -0.72 | +1.4% |
| Diluted EPS | -0.68 | -0.69 | -0.73 | -0.74 | -0.72 | +1.4% |
| EBIT | -$130.54M | -$137.36M | -$137.37M | -$137.43M | -$134.96M | +5.0% |
| EBITDA | -$126.06M | -$133.60M | -$133.58M | -$133.57M | -$131.01M | +5.6% |
| Basic shares | 187.31M | 186.64M | 175.46M | 172.42M | 171.45M | +0.4% |
| Diluted shares | 187.31M | 186.64M | 175.46M | 172.42M | 171.45M | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $201.53M | $387.63M | $205.33M | $90.96M | $141.21M | -48.0% |
| Cash & short-term investments | $710.47M | $987.68M | $867.88M | $848.20M | $898.95M | -28.1% |
| Accounts receivable | $3.93M | — | $2.18M | — | — | — |
| Inventory | $4.14M | — | — | — | — | — |
| Total current assets | $753.93M | $1.02B | $900.66M | $882.60M | $934.71M | -26.3% |
| Property, plant & equipment | $113.42M | $117.27M | $119.94M | $123.21M | $130.10M | -3.3% |
| Goodwill & intangibles | $35.25M | $36.00M | — | — | — | -2.1% |
| Total assets | $1.16B | $1.27B | $1.14B | $1.06B | $1.17B | -8.5% |
| Total current liabilities | $90.08M | $110.16M | $98.35M | $90.15M | $91.06M | -18.2% |
| Total debt | $32.21M | $34.54M | $36.76M | $44.40M | $46.56M | -6.8% |
| Total liabilities | $322.78M | $339.93M | $131.09M | $129.42M | $139.19M | -5.0% |
| Retained earnings | -$2.31B | -$2.18B | -$2.05B | -$1.92B | -$1.80B | -5.9% |
| Shareholder equity | $835.18M | $926.10M | $1.01B | $926.20M | $1.03B | -9.8% |
| Working capital | $663.84M | $912.60M | $802.31M | $792.45M | $843.65M | -27.3% |
| Net tangible assets | $799.93M | $890.10M | $1.01B | $926.20M | $1.03B | -10.1% |
| Shares issued | 159.76M | 158.66M | 156.18M | 146.63M | 145.69M | +0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$127.55M | -$128.45M | -$128.55M | -$126.90M | -$124.12M | — | +0.7% |
| Depreciation & amortisation | $4.48M | $3.76M | $3.78M | $3.86M | $3.96M | — | +19.2% |
| Stock-based compensation | $22.91M | $23.09M | $23.95M | $25.14M | $25.39M | — | -0.7% |
| Change in working capital | $382.00K | -$27.50M | $5.02M | -$6.22M | $23.29M | — | +101.4% |
| Operating cash flow | -$97.00M | -$131.20M | -$98.54M | -$107.30M | -$75.30M | — | +26.1% |
| Capital expenditure | -$29.61M | -$2.47M | -$1.52M | — | -$4.28M | -$5.08M | -1,100.5% |
| Investing cash flow | -$104.08M | $94.46M | $20.77M | $57.83M | $157.94M | — | -210.2% |
| Financing cash flow | $14.98M | $219.04M | $192.13M | -$778.00K | $1.62M | — | -93.2% |
| Free cash flow | -$126.61M | -$133.67M | -$100.06M | -$105.92M | -$79.58M | — | +5.3% |
| End cash position | $204.64M | $390.73M | $208.43M | $94.07M | $144.31M | — | -47.6% |
Options analytics
Put / call volume
0.31
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
15.00
-22.2% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
+6.2%
Puts bid over calls
Call volume
91
Contracts, this expiry
Put volume
28
Contracts, this expiry
Heaviest call OI
20.00
0 contracts
Heaviest put OI
15.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.47 | -0.68 | -45.5% |
| Mar 2026 | -0.71 | -0.69 | +2.3% |
| Dec 2025 | -0.75 | -0.73 | +2.5% |
| Sep 2025 | -0.76 | -0.74 | +2.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.37 | 17 | $22.90M | 0.0% |
| Next quarter | -0.62 | 17 | $24.45M | 0.0% |
| Current year | -2.22 | 17 | $50.57M | 0.0% |
| Next year | -2.42 | 17 | $129.52M | +156.1% |
Analyst targets & ownership
Mean target$36.06
High target$42.00
Low target$27.00
Implied upside87.05%
Analyst count16
ConsensusSTRONG BUY
Strong buy / Buy2 / 17
Hold1
Sell / Strong sell0 / 0
Held by insiders4.61%
Held by institutions101.29%
Institutions holding411
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
20.35
-5.26% from price
SMA 20
20.56
-6.21% from price
SMA 50
22.71
-15.10% from price
SMA 100
22.60
-14.68% from price
SMA 200
21.08
-8.55% from price
EMA 12
20.37
-5.33% from price
EMA 26
21.14
-8.81% from price
EMA 50
21.92
-12.04% from price
RSI (14)
31.7
Neutral
MACD (12,26,9)
-0.78
Hist 0.00
ATR (14)
0.86
4.45% of price
Realised vol 30D
35.2%
Annualised
Bollinger upper
21.77
20, 2σ
Bollinger lower
19.34
20, 2σ
50 / 200 cross
Golden
22.71 vs 21.08
Trend bias
Below 200
-8.55%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.48
More volatile than market
Correlation to SPY
0.34
Loosely linked
Realised vol 30D
35.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-29.1%
Peak to trough
Max drawdown 5Y
-79.2%
Peak to trough
ATR 14
0.86
4.45% of price
Beta (reported)
1.02
5Y monthly, from filing
Short interest
Shares short
17.14M
Prior 17.96M
Change vs prior
-4.6%
Shorts covering
% of float
11.31%
Elevated
% of shares out
10.72%
Against total outstanding
Days to cover
14.3
Crowded exit
Float
155.10M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 25, 26 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Aug 7, 26 | UBS | MAINTAINED | Buy | Buy |
| Jul 23, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Jul 16, 26 | Deutsche Bank | MAINTAINED | Buy | Buy |
| May 26, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| May 14, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| May 11, 26 | BTIG | MAINTAINED | Buy | Buy |
| May 8, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Apr 22, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Apr 7, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Mar 26, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Mar 26, 26 | Goldman Sachs | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-28
Corporate Changes & Voting Matters
8-K · 2026-06-18
Corporate Changes & Voting Matters
8-K · 2026-06-04
Corporate Changes & Voting Matters
8-K · 2026-05-22
Periodic Financial Reports
10-Q · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-21
Corporate Changes & Voting Matters
8-K · 2026-04-03
Headlines
Denali Therapeutics Insider Sold Shares Worth $261,929, According to a Recent SEC Filing
MT Newswires · 32d ago
B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating
MT Newswires · 43d ago
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
Zacks · 48d ago
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
Zacks · 48d ago
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript
Motley Fool · 54d ago
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
Zacks · 60d ago
UBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating
MT Newswires · 61d ago
Denali Therapeutics Inc. Q2 2026 Earnings Call Summary
Moby · 61d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.